This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cockerell, G. L. Articles by Vonderfecht, S. L. Search for Related Content PubMed PubMed Citation Articles by Cockerell, G. L. Articles by Vonderfecht, S. L. Social Bookmarking                         What's this?

Strategic Importance of Research Support through Pathology

Global Toxicology, Pharmacia Corporation, Kalamazoo, Michigan, USA, gary.l.cockerell{at}pharmacia.com

James M. Mckim, JR

Global Toxicology, Pharmacia Corporation, Kalamazoo, Michigan, USA

Steven L. Vonderfecht

Global Toxicology, Pharmacia Corporation, Kalamazoo, Michigan, USA

The pace at which new drug candidates are being identified by Discovery Research demands that they be screened for preclinical attributes rapidly and efficiently. The early identification and elimination of compounds with toxic liabilities will produce safer drugs in a shorter time period, and with an increased rate of success. Most major pharmaceutical companies now recognize the strategic role of pathology support for research and have developed specific units to effect this outcome. The early interaction of these pathologists with drug discovery teams to identify compounds with toxic liabilities is critical. Approache s being used include high throughput in vitro screens to predict the relative toxicity of discovery compounds and to provide early indications of underlying mechanisms, target profiling to predict consequences of receptor-ligand interactions at other-than-indicated target sites, and acute in vivo studies to establish tolerability limits and target organs of toxicity. These approaches include the application of contemporary tools such as genomics, proteomics, metabonomics, and genetically engineered animal models. To maximize the benefit of discovery pathology, it is critical that pharmaceutical companies also actively participate in non-proprietary knowledge sharing and the education of pathologists and toxicologists to lead these efforts in the future.

Key Words: Benchmarking • education • investigative pathology and toxicology • in vitro toxicity screens • target organs of toxicity • target profiling • toxicology.

Toxicologic Pathology, Vol. 30, No. 1, 4-7 (2002)
DOI: 10.1080/01926230252824644


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?